GlaxoSmithKline

The ax drops on hundreds at Human Genome Sciences in wake of GSK buyout

3 Reasons Novartis Creates Long-Term Opportunity

Research and Markets: ChemoCentryx's and GSK's Traficet-EN (Vercirnon) for Crohn's Disease

Bad Pharma by Ben Goldacre – review

Boost to partner with McLaren F1 team

FDA News to hold a summit

GlaxoSmithKline - A Few Reasons Not To Buy In Now

Jobs saved as GSK decides to keep Irish plant open

Eli Lilly Worth Long-Term Risk Investment

Competition Creates Uncertainty For AstraZeneca